Biomarkers of over-immunosuppression

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 316-322

  Budde, K ^a   Matz, M ^a   Durr M ^a   Glander, P ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; GRAFT RECIPIENT; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; TRANSPLANTATION TOLERANCE;

BIOMARKERS, PHARMACOLOGICAL; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

EID: 79960592783     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.111     Document Type: Article

References (40)

1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
2. Lachenbruch, P.A., Rosenberg, A.S., Bonvini, E., Cavaill Coll, M.W. & Colvin, R.B. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am. J. Transplant. 4, 451-457 (2004). (Pubitemid 38523567)
3. Pilmore, H., Dent, H., Chang, S., McDonald, S.P. & Chadban, S.J. Reduction in cardiovascular death after kidney transplantation. Transplantation 89, 851-857 (2010).
4. Hirsch, H.H. & Randhawa, P.; AST Infectious Diseases Community of Practice. BK virus in solid organ transplant recipients. Am. J. Transplant. 9 (suppl. 4), S136-S146 (2009).
5. Fishman, J.A. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357, 2601-2614 (2007). (Pubitemid 350294226)
6. Rama, I. & Griny J.M.; Medscape. Malignancy after renal transplantation: the role of immunosuppression. Nat. Rev. Nephrol. 6, 511-519 (2010).
7. Webster, A.C., Wong, G., Craig, J.C. & Chapman, J.R. Managing cancer risk and decision making after kidney transplantation. Am. J. Transplant. 8, 2185-2191 (2008).
8. Halloran, P.F., Bromberg, J., Kaplan, B. & Vincenti, F. Tolerance versus immunosuppression: a perspective. Am. J. Transplant. 8, 1365-1366 (2008). (Pubitemid 351989509)
9. Newell, K.A. & Larsen, C.P. Tolerance assays: measuring the unknown. Transplantation 81, 1503-1509 (2006). (Pubitemid 43890885)
10. Danger, R., Racap M., Soulillou, J.P. & Brouard, S. What can we learn from the transcriptional characterization of spontaneously tolerant transplant recipients? Curr. Opin. Organ Transplant. 15, 435-440 (2010).
11. Babel, N., Reinke, P. & Volk, H.D. Lymphocyte markers and prediction of longterm renal allograft acceptance. Curr. Opin. Nephrol. Hypertens. 18, 489-494 (2009).
12. Sawitzki, B., Pascher, A., Babel, N., Reinke, P. & Volk, H.D. Can we use biomarkers and functional assays to implement personalized therapies in transplantation? Transplantation 87, 1595-1601 (2009).
13. Mill, O., Urtasun, N. & Brunet, M. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients. Transplant. Rev. (Orlando). 23, 120-128 (2009).
14. Wieland, E. et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther. Drug Monit. 32, 560-572 (2010).
15. Nickerson, P. Post-transplant monitoring of renal allografts: are we there yet? Curr. Opin. Immunol. 21, 563-568 (2009).
16. Budde, K. & Glander, P. Pharmacokinetic principles of immunosuppressive drugs. Ann. Transplant. 13, 5-10 (2008).
17. Dantal, J. et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351, 623-628 (1998). (Pubitemid 28098444)
18. Glander, P. & Budde, K. Target enzyme activity as a biomarker for immunosuppression. Ther. Drug Monit. 32, 257-260 (2010).
19. Abouna, G.M. et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 59, 1564-1568 (1995).
20. Ducloux, D. et al. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J. Am. Soc. Nephrol. 21, 868-875 (2010).
21. Thibaudin, D., Alamartine, E., Mariat, C., Absi, L. & Berthoux, F. Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation 80, 1514-1517 (2005). (Pubitemid 41803636)
22. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 9(suppl. 3) S1-155 (2009).
23. Sommerer, C., Giese, T., Meuer, S. & Zeier, M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol. Dial. Transplant. 24, 21-27 (2009).
24. van Rossum, H.H., de Fijter, J.W. & van Pelt, J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther. Drug Monit. 32, 3-10 (2010).
25. Mortensen, D.M., Re, R., Szbay, A., Koefoed-Nielsen, P.B. & Jigensen, K.A. Gene expression analysis of calcineurin isoforms in T-lymphocytes-a method applied on kidney-transplant recipients. Transpl. Immunol. 23, 24-27 (2010).
26. Di Paolo, S., Teutonico, A., Ranieri, E., Gesualdo, L. & Schena, P.F. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma. Am. J. Kidney Dis. 49, 462-470 (2007).
27. Gutirez-Dalmau, A. et al. Distinct immunohistochemical phenotype of nonmelanoma skin cancers between renal transplant and immunocompetent populations. Transplantation 90, 986-992 (2010).
28. Dekter, H.E., Romijn, F.P., Temmink, W.P., van Pelt, J., de Fijter, J.W. & Smit, N.P. A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal. Biochem. 403, 79-87 (2010).
29. Krer, B., Schrpel, B. & Murphy, B.T. Genetic polymorphisms and the fate of the transplanted organ. Transplant. Rev. (Orlando). 22, 131-140 (2008). (Pubitemid 351372915)
30. de Jonge, H. & Kuypers, D.R. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant. Rev. (Orlando). 22, 6-20 (2008). (Pubitemid 350131580)
31. Krer, B. et al. A comprehensive genotype-phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clin. Sci. 119, 535-544 (2010).
32. Cattaneo, D. et al.; Mycophenolate Steroids Sparing (MYSS) Genetics Study G roup. ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J. Am. Soc. Nephrol. 20, 1404-1415 (2009).
33. Babel, N. et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation 84, 387-391 (2007). (Pubitemid 47258328)
34. Kotton, C.N. et al.; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89, 779-795 (2010).
35. Kumar, D. et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9, 1214-1222 (2009).
36. Eid, A.J. et al. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl. Int. 23, 506-513 (2010).
37. Wang, D. et al. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients. Transpl. Immunol. 22, 115-120 (2010).
38. Carroll, R.P. et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J. Am. Soc. Nephrol. 21, 713-722 (2010).
39. US Food and Drug Administration. Summary and approval for CD4 cell stimulation assay (2010).
40. Kobashigawa, J.A. et al. Benefit of immune monitoring in heart transplant patients using AT P production in activated lymphocytes. J. Heart Lung Transplant. 29, 504-508 (2010).